Alice Hurrell, Jenie Sparkes, Kate Duhig, Paul T Seed, Jenny Myers, Cheryl Battersby, Katherine Clark, Marcus Green, Rachael M Hunter, Andrew H Shennan, Lucy C Chappell, Louise Webster
BACKGROUND: Pre-eclampsia is a complex pregnancy disorder, characterised by new or worsening hypertension associated with multi-organ dysfunction. Adverse outcomes include eclampsia, liver rupture, stroke, pulmonary oedema, and acute kidney injury in the mother, and stillbirth, foetal growth restriction, and iatrogenic preterm delivery for the foetus. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women...
September 2, 2022: Trials